Expanding Into a Biosimilar Portfolio

As biosimilars differ from traditional generics in their safety profiles and regulatory requirements, sponsors must adapt existing pharmacovigilance systems while meeting tight timelines across EU and US markets. The focus is shifting from standard PV execution to a tailored, biosimilar-specific strategy that ensures compliance, market readiness, and long-term competitiveness.

Read this case study to explore more about:
– Integrating biosimilars into global pharmacovigilance systems
– Meeting EU and US biosimilar safety and regulatory requirements
– Using signal management and RMPs to support approvals
– Scaling pharmacovigilance efficiently in competitive markets